Clinical Trial Update: A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A [Phase 1]

View source ↗

Summary

Phase I study update reporting safety and immunogenicity results for TB vaccine candidates FP85A and MVA85A; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• FP85A
• MVA85A (Modified Vaccinia Ankara expressing antigen 85A)

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED